Latest Trending
Last Updated, Nov 2, 2023, 3:48 PM
Obesity Drug Demand Outstrips Supply


Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question. 

Both Lilly and its competitor, Denmark’s Novo Nordisk, which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications. There is no quick fix for that given the complexity of building out manufacturing capacity for the injections. Both companies are investing billions of dollars a year to try to catch up.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8



Source link

24World Media does not take any responsibility of the information you see on this page. The content this page contains is from independent third-party content provider. If you have any concerns regarding the content, please free to write us here: contact@24worldmedia.com

Latest Post

Letter: I’m proud to vote for Seth Moulton

Last Updated,Aug 27, 2026

Letter: I support Tram T. Nguyen for Congress

Last Updated,Aug 27, 2026

Team of the Week – Peabody West (12U)

Last Updated,Aug 27, 2026

Gleb Tsipursky, PhD: Lynn employers should give AI-era beginners a first project

Last Updated,Aug 26, 2026

Aboyoun: It was never about women

Last Updated,Aug 26, 2026

Lynn’s Katie Burt scores Providence College promotion

Last Updated,Aug 26, 2026

Peabody playground set to honor Pantapas

Last Updated,Aug 26, 2026

Lynn aligns with state on immigration enforcement

Last Updated,Aug 26, 2026

Saugus’ Angelo honored for extraordinary service

Last Updated,Aug 26, 2026

Swampscott seawall repairs pending state review

Last Updated,Aug 26, 2026

Young Lynnfield entrepreneur cleaning up

Last Updated,Aug 26, 2026

For Peabody sisters, Walk for Hospice is a family tradition

Last Updated,Aug 26, 2026